Intellipharmaceutics International Inc
TSX:IPCI
Intellipharmaceutics International Inc
Research & Development
Intellipharmaceutics International Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Intellipharmaceutics International Inc
TSX:IPCI
|
Research & Development
-$1.7m
|
CAGR 3-Years
23%
|
CAGR 5-Years
30%
|
CAGR 10-Years
10%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Research & Development
-$631m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Research & Development
-$4.1m
|
CAGR 3-Years
38%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Research & Development
-$105.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
-152%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Research & Development
-CA$27.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-26%
|
|
Intellipharmaceutics International Inc
Glance View
Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company is headquartered in Etobicoke, Ontario. The firm is specializing in the research, development and manufacture of generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products and product candidates in various stages of development, in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its Paradoxical OverDose Resistance Activating System (PODRAS) delivery technology is designed to prevent overdose when more pills than prescribed are swallowed intact. Its product and product candidates include Generic Focalin XR, Generic Keppra XR, Generic Glucophage XR and Generic Effexor XR, among others.
See Also
What is Intellipharmaceutics International Inc's Research & Development?
Research & Development
-1.7m
USD
Based on the financial report for Aug 31, 2023, Intellipharmaceutics International Inc's Research & Development amounts to -1.7m USD.
What is Intellipharmaceutics International Inc's Research & Development growth rate?
Research & Development CAGR 10Y
10%
Over the last year, the Research & Development growth was 47%. The average annual Research & Development growth rates for Intellipharmaceutics International Inc have been 23% over the past three years , 30% over the past five years , and 10% over the past ten years .
